2026-06-22T09:46:20-05:00 2025-12-31 954611603 HENSIEK & CARON CPA'S 650 SIERRA MADRE VILLA 303 PASADENA CA 91107 990 2025-01-01 954310830 CELIAC DISEASE FOUNDATION CELI 8187161513 21300 VICTORY BLVD 300 WOODLAND HILLS CA 91367 MARILYN GRUNZWEIG GELLER CEO 8187161513 2026-06-15 1 SUSAN CARON P00163651 6267929988 2025 2025-03-06 01:10:19Z X MARILYN GRUNZWEIG GELLER 21300 VICTORY BLVD 300 WOODLAND HILLS CA 91367 6203837 0 X WWW.CELIAC.ORG X 1990 CA THE CELIAC DISEASE FOUNDATION DRIVES DIAGNOSIS, TREATMENT AND A CURE THROUGH RESEARCH, ADVOCACY AND EDUCATION. 15 15 18 20323 0 0 2407287 2568848 1662305 2389372 151072 149308 73689 208353 4294353 5315881 572500 355540 0 0 2280100 2590343 0 0 599795 1483474 1634106 4336074 4579989 -41721 735892 7559145 8297238 2000126 1467942 5559019 6829296 X THE CELIAC DISEASE FOUNDATION IS THE LEADING GLOBAL PATIENT ADVOCACY ORGANIZATION COMMITTED TO ACCELERATING DIAGNOSIS, TREATMENTS, AND A CURE FOR CELIAC DISEASE. OUR MISSION IS TO IMPROVE THE HEALTH AND WELL-BEING OF THE MILLIONS OF INDIVIDUALS AROUND THE WORLD AFFECTED BY THIS GENETIC AUTOIMMUNE DISEASE THROUGH OUR STRATEGIC INVESTMENTS IN RESEARCH, ADVOCACY, AND EDUCATION. 0 0 3189546 355540 2386650 RESEARCHTHE CELIAC DISEASE FOUNDATION MAKES STRATEGIC INVESTMENTS IN CUTTING-EDGE BIOMEDICAL RESEARCH AND COLLABORATES WITH RESEARCHERS AND CLINICIANS TO ADVANCE UNDERSTANDING OF AND TREATMENTS FOR CELIAC DISEASE. IN 2025, THE FOUNDATION AWARDED NEARLY $500,000 IN BREAKTHROUGH GRANTS FOCUSED ON IMMUNE RESPONSE TO GLUTEN AND DISEASE ONSET, FUNDING PROJECTS AT BOSTON CHILDREN'S HOSPITAL, UC DAVIS, COLORADO CHILDREN'S HOSPITAL, CHILDREN'S NATIONAL HOSPITAL, AND BETH ISRAEL DEACONESS MEDICAL CENTER. THE FOUNDATION SPONSORED MAJOR SCIENTIFIC GATHERINGS INCLUDING THE TAMPERE CELIAC DISEASE SYMPOSIUM, THE COLUMBIA UNIVERSITY CELIAC DISEASE ON THE HORIZON CONFERENCE, THE NASPGHAN SINGLE TOPIC SYMPOSIUM, AND THE COLORADO SCREENING SYMPOSIUM. IN A LANDMARK PARTNERSHIP, THE NORTH AMERICAN SOCIETY FOR THE STUDY OF CELIAC DISEASE (SSCD) BECAME THE FOUNDATION'S SCIENTIFIC ADVISORY COMMITTEE. THE FOUNDATION'S CLINICAL TRIAL RECRUITMENT PLATFORM, IQUALIFYCELIAC, SURPASSED 34,000 PARTICIPATING PATIENTS, WHILE IRECRUITCELIAC SUPPORTED 9 ACTIVE TRIALS ACROSS 9 NEW GLOBAL PARTNER ORGANIZATIONS ON 3 CONTINENTS. THE FOUNDATION ALSO LAUNCHED THE FIRST-EVER CELIAC DISEASE CLINICAL TRIAL SITE ADVISORY COUNCIL AND THE CELIAC DISEASE FOUNDATION IMPACT FUND, A VENTURE PHILANTHROPY VEHICLE TO FAST-TRACK BREAKTHROUGH THERAPIES AND DIAGNOSTICS FROM LAB TO PATIENT.________________________________________ADVOCACYIN 2025, THE CELIAC DISEASE FOUNDATION AFFIRMED ITS ROLE AS THE LEADING VOICE FOR CELIAC DISEASE POLICY. THE NIH ALLOCATED $10 MILLION FOR CELIAC DISEASE RESEARCH IN FY2025, AND CELIAC DISEASE WAS INCLUDED FOR THE THIRD CONSECUTIVE YEAR IN THE DEPARTMENT OF DEFENSE PEER REVIEWED MEDICAL RESEARCH PROGRAM, WITH $1.58 MILLION AWARDED. ADVOCATES FROM 14 STATES ATTENDED THE 2025 ADVOCACY SUMMIT AND HILL DAY, MEETING WITH 30 BIPARTISAN CONGRESSIONAL OFFICES AND SENDING MORE THAN 5,000 ADVOCACY EMAILS. ADVOCATES FROM ALL 50 STATES SUBMITTED CELIAC DISEASE AWARENESS MONTH PROCLAMATION REQUESTS, SECURING A RECORD 27 STATES AND WASHINGTON, D.C. CEO MARILYN G. GELLER REPRESENTED CELIAC PATIENTS AT THE 48TH SESSION OF THE CODEX COMMITTEE ON FOOD LABELLING IN QUEBEC CITY, SECURING AMENDED LABELING TEXT, INCLUSION OF CELIAC DISEASE IN MANDATORY PREPACKAGED FOOD LABELING AND PRECAUTIONARY ALLERGEN LABELING GUIDELINES, AND A CALL FOR EXPERTS TO INFORM SETTING A GLUTEN THRESHOLD. THE FOUNDATION ALSO CONVENED THE GLOBAL CELIAC ADVOCACY ALLIANCE, UNITING PATIENT ADVOCACY LEADERS FROM 12 ORGANIZATIONS ACROSS 6 CONTINENTS.________________________________________EDUCATIONTHE CELIAC DISEASE FOUNDATION PROVIDES INNOVATIVE TOOLS AND PROGRAMMING TO PROMOTE CELIAC DISEASE EDUCATION FOR PATIENTS, FAMILIES, AND HEALTHCARE PROFESSIONALS. THROUGH CELIAC.ORG, THE FOUNDATION OFFERS A SYMPTOMS ASSESSMENT TOOL, A NATIONWIDE PRACTITIONER DIRECTORY, EAT! GLUTEN-FREE MEAL PLANS, AND THE CELIAC DISEASE MANAGEMENT PLAN FOR SCHOOL TRAINING PROGRAM. VIRTUAL PROGRAMMING - INCLUDING CULINARY MEDICINE WEBINARS NOW AVAILABLE WITH LIVE SPANISH AND PORTUGUESE TRANSLATION - REACHED OVER 1,000 PATIENTS AND 200 HEALTHCARE PROFESSIONALS IN 2025. THE FOUNDATION CONVENED THE COLLEGE CONSENSUS SUMMIT TO DEVELOP THE FIRST-EVER NATIONAL RECOMMENDATIONS FOR SUPPORTING COLLEGE STUDENTS WITH CELIAC DISEASE, AND LAUNCHED THE CELIAC DISEASE FOUNDATION DIETITIAN ADVISORY COUNCIL. TOOLS FOR HEALTHCARE PROFESSIONALS INCLUDE THE NASPGHAN CLINICAL GUIDE FOR PEDIATRIC CELIAC DISEASE, THE CELIAC DISEASE AND PSYCHOLOGICAL HEALTH TRAINING PROGRAM, AND ACCREDITED CME/CEU PROGRAMS. THE FOUNDATION REACHES A GLOBAL AUDIENCE THROUGH CELIAC.ORG, SOCIAL MEDIA CHANNELS WITH OVER 250,000 FOLLOWERS AND 25 MILLION VIEWS, AND AN E-NEWSLETTER WITH MORE THAN 100,000 SUBSCRIBERS. 3189546 1 1 0 0 0 0 0 0 0 0 1 1 0 0 0 1 0 1 0 0 0 0 0 0 1 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 36 0 18 1 0 0 0 0 0 0 0 0 0 0 0 0 X 15 15 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 CA X X X THE ORGANIZATION 8187161513 21300 VICTORY BLVD 300 WOODLAND HILLS CA 91367 X BRADLEY HERREMA BOARD SECRETARY 2.00 X X 0 0 0 JOHN WAGNER GOVERNMENT & ADVOCACY COMMITTEE CHAIR 2.00 X X 0 0 0 WARREN SAFT TREASURER 2.00 X X 0 0 0 ADRIENNE BENDER VICE CHAIR 2.00 X X 0 0 0 LEE JONES BOARD GOVERNANCE CO-CHAIR 2.00 X 0 0 0 JAMIE RESIN MEMBER 2.00 X 0 0 0 BETH BLUE MEMBER 2.00 X 0 0 0 DAN GIBBONS MEMBER 2.00 X 0 0 0 KRISTIN YAREMA MEMBER 2.00 X 0 0 0 GREG FRASCA MEMBER 2.00 X 0 0 0 JORDAN RAMER BOARD GOVERNANCE CO-CHAIR 2.00 X 0 0 0 JENNIFER SULLIVAN MEMBER 2.00 X 0 0 0 BLAKELY BRANIFF DEVELOPMENT COMMITTEE CHAIR 2.00 X 0 0 0 WILLIAM THURSTON BOARD CHAIR 2.00 X X 0 0 0 KAREN WICKER MEMBER 2.00 X 0 0 0 MARILYN GRUNZWEIG GELLER CEO 40.00 X 350580 0 56486 BRETT SPITALE CHIEF OF STAFF 40.00 X 223440 0 33831 VANESSA WEISBROD CHIEF EDUCATION & COMMUNIT 40.00 X 186408 0 42507 760428 0 132824 8 0 1 0 0 2568848 2568848 PROGRAM INCOME 900099 2012580 2012580 SPONSORSHIPS 900099 376792 376792 2389372 152220 152220 853777 853967 2722 -190 -2722 -2912 -2722 -190 239620 31267 208353 208353 5315881 2386650 0 360383 351540 351540 4000 4000 760428 288498 325152 146778 1325936 979929 129242 216765 119007 72351 25919 20737 236816 143975 51577 41264 148156 90073 32267 25816 16000 16000 16500 16500 132539 115718 11680 5141 42430 34221 6709 1500 94333 7972 86361 12221 11243 489 489 81279 69439 11840 180167 163736 9224 7207 21774 11915 8444 1415 EDUCATION AND COMMUNITY 440107 440107 CLINICAL TRIALS 246967 246967 SCIENTIFIC AFFAIRS 116967 116967 ADVOCACY 108158 108158 124664 2176 1645 120843 4579989 3189546 790648 599795 1188056 1783187 816533 0 188026 374095 255730 511450 31593 29803 1215498 672087 702175 543411 4297334 4886731 0 88743 79698 79818 7559145 8297238 939503 602394 734092 509132 326531 356416 2000126 1467942 X 5559019 6610016 219280 5559019 6829296 7559145 8297238 735892 534385 0 X 0 1 X 1 0 X 1708692 1497173 2283348 2506162 2808468 10803843 1708692 1497173 2283348 2506162 2808468 10803843 10803843 23919 27932 90475 151617 152220 446163 11250006 8728132 0.96030 0.96870 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1215498 672087 543411 543411 MUTUAL FUNDS 4655064 F MONEY MARKET FUNDS 231667 F 4886731 X PART X, LINE 2: THE ACCOUNTING STANDARD ON ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES PROVIDES GUIDANCE ON HOW UNCERTAIN TAX POSITIONS SHOULD BE RECOGNIZED, MEASURED, PRESENTED AND DISCLOSED IN THE FINANCIAL STATEMENTS. EXAMPLES OF TAX POSITIONS INCLUDE THE TAX-EXEMPT STATUS OF THE FOUNDATION AND VARIOUS POSITIONS RELATED TO THE POTENTIAL SOURCES OF UNRELATED BUSINESS TAXABLE INCOME (UBIT). THE FOUNDATION BELIEVES THAT IT HAS NO UNCERTAIN TAX POSITIONS THAT IMPACT ITS FINANCIAL STATEMENTS. TURKEY TROT 111525 111525 17882 ENDURANCE TEAMS 90887 90887 10244 1 37208 37208 3141 239620 239620 31267 31267 208353 1 NASPGHAN 714 N BETHLEHEM PIKE 300 AMBLER PA 19002 25000 0 CELIAC DISEASE RESEARCH BETH ISRAEL DEACONESS MEDICAL CENTER INC 330 BROOKLINE AVE BOSTON MA 02215 100000 0 CELIAC DISEASE RESEARCH NORTH CAROLINA STATE UNIVERSITY 3200 ATLANTIC AVE RALEIGH NC 27604 67500 0 CELIAC DISEASE RESEARCH UC DAVIS PO BOX 743739 LOS ANGELES CA 90074 97500 0 CELIAC DISEASE RESEARCH CHILDRENS HOSPITAL CORP 1295 BOYLSTON ST 4TH FLOOR BOSTON MA 02215 61540 0 CELIAC DISEASE RESEARCH TRAVEL GRANT 4 4000 1 X X X X X 0 0 0 0 0 0 0 0 0 MARILYN GRUNZWEIG GELLER CEO 350580 0 0 0 0 0 32752 0 23734 0 407066 0 0 0 BRETT SPITALE CHIEF OF STAFF 223440 0 0 0 0 0 13871 0 19960 0 257271 0 0 0 VANESSA WEISBROD CHIEF EDUCATION & COMMUNIT 186408 0 0 0 0 0 23776 0 18731 0 228915 0 0 0 FORM 990, PART VI, SECTION B, LINE 11B THE 990 IS REVIEWED BY THE CEO AND THE FINANCE COMMITTEE BEFORE FILING. FORM 990, PART VI, SECTION B, LINE 12C BOARD MEMBERS ARE REQUIRED TO DISCLOSE ANY ACTUAL, POTENTIAL, OR PERCEIVED CONFLICTS OF INTEREST AT TIME OF APPOINTMENT, ANNUALLY AND AS THEY ARISE; DISCLOSED CONFLICTS ARE REVIEWED AND MANAGED IN ACCORDANCE WITH THE FOUNDATION'S CONFLICT OF INTEREST POLICY. FORM 990, PART VI, SECTION B, LINE 15 THE BOARD OF DIRECTORS REVIEWS COMPENSATION FOR THE CEO ANNUALLY TO DETERMINE THAT THE COMPENSATION IS REASONABLE. FORM 990, PART VI, SECTION C, LINE 19 THE 990 IS REVIEWED BY THE CHIEF EXECUTIVE OFFICER BEFORE FILING AND THE FINANCE COMMITTEE OF THE BOARD OF DIRECTORS. CELIAC DISEASE FOUNDATION IMPACT FUND LLC 21300 VICTORY BLVD 300 WOODLAND HILLS CA 91367 394420341 RESEARCH AND DEVELOP THERAPIES TO TREAT CELIAC DISEASE DE 600000 407361 CELIAC DISEASE FOUNDATION